LAKE SUCCESS, N.Y.--(BUSINESS WIRE)--E-Z-EM, Inc. (NASDAQ:EZEM) today announced financial results for its fiscal 2008 first quarter. Highlights for the quarter ended September 1, 2007 and recent weeks included: Net sales from continuing operations of $33.0 million Earnings from continuing operations of $0.65 million, or $0.06 per diluted share Formal launch of the Company’s new EZ CHEMTM blood analyzer Addition of EmpowerMR® to group purchasing contract with Amerinet Receipt of approximately $12.5 million of follow-on orders for RSDLTM skin decontaminant from the U.S. Department of Defense (DoD), and transfer of 510(k) title for RSDL to E-Z-EM Announcement of favorable clinical results for virtual colonoscopy from the ACRIN II study
